Protein aggregation has been recognized as one of the major challenges in the
development and commercialization of successful protein-based drug products because of …

Introduction: Many of the biotherapeutics approved or under development suffer from a short
half-life necessitating frequent applications in order to maintain a therapeutic concentration …

Background The inflammatory contribution to type 2 diabetes (T2D) has suggested new
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis …

Administration into the subcutaneous (SC) tissue is a typical route of delivery for therapeutic
proteins, especially for frequent treatments, long-term regimens, or self-administration. It is …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Since several decades, PEGylation is known to be the clinical standard to enhance
pharmacokinetics of biotherapeutics. In this study, we introduce polyglycerol (PG) of different …

Asymmetrical flow field-flow fractionation (AF4) has attracted considerable attention as a
size-based separation technique, due to its mild separation conditions, broad working range …

Biocompatible polymers such as poly (ethylene glycol)(PEG) have been successfully
conjugated to therapeutic proteins to enhance their pharmacokinetics. However, many of …

The pharmaceutical market has largely been dominated by small molecule drugs; however,
larger biomolecules have recently become important contenders. Of these biomolecules …

The advantageous biological properties of hydroxyethyl starch (HES) triggered research
interest toward the design and synthesis of drug delivery systems (DDSs) based on this …